Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Oncternal Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ONCT
Nasdaq
8731
https://www.oncternal.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Oncternal Therapeutics Inc
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
- Apr 18th, 2024 1:00 pm
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
- Mar 15th, 2024 1:00 pm
Oncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
- Mar 10th, 2024 2:38 pm
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
- Mar 7th, 2024 9:01 pm
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
- Feb 29th, 2024 9:05 pm
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 9:30 pm
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Feb 1st, 2024 2:00 pm
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
- Jan 8th, 2024 2:00 pm
Oncternal Therapeutics Announces Reverse Stock Split
- Jan 4th, 2024 2:00 pm
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
- Dec 26th, 2023 2:00 pm
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript
- Nov 11th, 2023 4:06 pm
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
- Nov 9th, 2023 9:01 pm
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results
- Nov 2nd, 2023 8:05 pm
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Oct 26th, 2023 1:00 pm
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board
- Oct 25th, 2023 1:00 pm
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
- Oct 5th, 2023 8:01 pm
We're A Little Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
- Sep 17th, 2023 1:30 pm
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
- Sep 7th, 2023 1:00 pm
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
- Aug 10th, 2023 8:01 pm
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
- Aug 3rd, 2023 8:30 pm
Scroll